Company Dossier · Health Care
Elevance Health
- S&P 500
- Russell 1000
What Elevance Health is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $201 billion, up 6.3% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $6.29 billion, up 18% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $1.18 billion, up 5.4% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $2.61 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $2.99 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (October 21, 2026): sentiment 0.65 on a −1 to +1 scale (mixed), confidence 0.85 of 1.Palanor Discourse
- Guidance in the last 90 days: 3 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 6, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net buyers in Q3 2026: $1.4 million on the open market.SEC Form 4
- 1,616 institutional managers reported a position at June 30, 2026 (+143 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 141 (160 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Elevance Health is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Confident
Expanding ↔ Retrenching
Steady
- Capital spending66th pct
- Debt raised—
- Buybacks vs capex53rd pct
- Hiring filings6th pct
- Deals and private raises49th pct
- Patent publications67th pct
Confident ↔ Hedging
Confident
- Call sentiment76th pct
- Call confidence84th pct
- Guidance changes91st pct
- Risk factors added81st pct
- Insider open-market trades82nd pct
- + Guidance changes
- + Call confidence
- + Call sentiment
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver10th pct
- Stress filings48th pct
Credit
How these are built →Elevance Health's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$30.8B
- Due within a year $0.4B
- Longer term $30.4B
- Default point $15.6B (short + ½ long)
Finance leases included · Sep 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Sep 8, 2025 | — | 5.700% | 2055 (30y) | +105bp | 5.740% |
| Sep 8, 2025 | — | 5.000% | 2036 (10y) | +100bp | 5.046% |
| Sep 8, 2025 | — | 4.000% | 2028 (3y) | +55bp | 4.019% |
| Sep 8, 2025 | — | 4.600% | 2032 (7y) | +85bp | 4.630% |
| Oct 22, 2024 | — | 4.750% | 2030 (5y) | +80bp | 4.796% |
| Oct 22, 2024 | — | 4.500% | 2026 (2y) | +48bp | 4.510% |
| Oct 22, 2024 | — | 5.200% | 2035 (10y) | +105bp | 5.246% |
| Oct 22, 2024 | — | 5.700% | 2055 (30y) | +125bp | 5.739% |
| Oct 22, 2024 | — | 5.850% | 2064 (40y) | +138bp | 5.869% |
| Oct 22, 2024 | — | 4.950% | 2031 (7y) | +90bp | 4.991% |
| May 20, 2024 | — | 5.150% | 2029 (5y) | +70bp | 5.155% |
| May 20, 2024 | — | 5.650% | 2054 (30y) | +110bp | 5.678% |
From the pricing term sheets Elevance Health filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (CAPITOL HILL CONSULTING GROUP)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (ELEVANCE HEALTH, INC.)third_quarter 2026 · $1.4 million
- Oct 20, 2026LobbyingLobbying report (TARPLIN, DOWNS & YOUNG, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (ALB SOLUTIONS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (MEHLMAN CONSULTING, INC.)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (TIBER CREEK GROUP)third_quarter 2026 · $0.1 million
- Oct 19, 2026LobbyingLobbying report (CONTINENTAL STRATEGY, LLC)third_quarter 2026 · $0.1 million
- Oct 6, 2026Patent
- Oct 1, 2026Trademark
- Aug 18, 2026Patent
- Aug 12, 2026Trademark
- Aug 11, 2026LobbyingLobbying report (CONTINENTAL STRATEGY, LLC)third_quarter 2025 · $0.1 million
- Jul 28, 2026Patent
- Jun 16, 2026Patent
- May 26, 2026Patent
- May 13, 20268-KShareholder vote resultsItem 5.07
- Feb 26, 20268-KDirector or officer changeItem 5.02
- Feb 6, 202610-KAnnual report (10-K)0 risk factors added, 0 removed
- Jan 15, 2026Trademark
- Dec 10, 20258-KDirector or officer changeItem 5.02
- Jul 28, 20258-KDirector or officer changeItem 5.02
- May 14, 20258-KShareholder vote resultsItem 5.07
- Feb 20, 202510-KAnnual report (10-K)2 risk factors added, 0 removed
- Feb 21, 202410-KAnnual report (10-K)1 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Centene Corporation CNC | $179B | $8.9B | Jun 30, 2026 |
| Humana HUM | $137B | $1.3B | Mar 31, 2026 |
| Molina Healthcare MOH | $44.5B | −$0.6B | Jun 30, 2026 |
| Cardinal Health CAH | $245B | $5.5B | Dec 31, 2025 |
| Cigna CI | $282B | — | Jun 30, 2026 |
| Cencora COR | $333B | $4.1B | Jun 30, 2026 |
| McKesson Corporation MCK | $411B | $6.4B | Jun 30, 2026 |
| Johnson & Johnson JNJ | $97.9B | $22.2B | Jun 28, 2026 |